Twin Capital Management Inc. Decreases Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Twin Capital Management Inc. lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,192 shares of the pharmaceutical company’s stock after selling 162 shares during the period. Twin Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $2,519,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in VRTX. Sherbrooke Park Advisers LLC lifted its position in shares of Vertex Pharmaceuticals by 65.3% during the 3rd quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock worth $920,000 after purchasing an additional 1,045 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its stake in Vertex Pharmaceuticals by 6.5% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 432,937 shares of the pharmaceutical company’s stock worth $150,550,000 after acquiring an additional 26,523 shares in the last quarter. Telos Capital Management Inc. increased its stake in Vertex Pharmaceuticals by 1.6% in the fourth quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock valued at $6,133,000 after purchasing an additional 237 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Vertex Pharmaceuticals by 1.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 427,001 shares of the pharmaceutical company’s stock valued at $148,485,000 after purchasing an additional 5,514 shares during the period. Finally, Machina Capital S.A.S. acquired a new position in Vertex Pharmaceuticals in the third quarter valued at $816,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on VRTX shares. JPMorgan Chase & Co. lifted their price objective on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Truist Financial lifted their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Sanford C. Bernstein lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, February 2nd. StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 12th. Finally, Canaccord Genuity Group reiterated a “sell” rating and set a $371.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, April 12th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $429.45.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $393.48 on Friday. The firm has a 50 day simple moving average of $414.17 and a 200-day simple moving average of $396.74. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. The firm has a market cap of $101.70 billion, a PE ratio of 28.33, a P/E/G ratio of 1.85 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 1-year low of $316.43 and a 1-year high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. The business had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same quarter in the previous year, the business posted $3.33 earnings per share. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Insider Transactions at Vertex Pharmaceuticals

In other news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Insiders sold 12,381 shares of company stock valued at $5,203,249 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.